Cellular and synaptic network defects in autism

Current Opinion in Neurobiology

Volumn 22, Issue 5, 2012, Pages 866-872

  Peça, João ^a   Feng, Guoping ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; NEUREXIN; NEUREXIN 1; NEUROLIGIN; NEUROLIGIN 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; SYNAPTIC PROTEIN; TSC1 PROTEIN; TUBERIN; UNCLASSIFIED DRUG;

AUTISM; DISEASE PREDISPOSITION; FRAGILE X SYNDROME; GENE; GENE FUNCTION; GLUTAMATERGIC SYNAPSE; HAPPY PUPPET SYNDROME; HUMAN; MULTIGENE FAMILY; NERVE CELL NETWORK; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SHANK GENE; SYNAPSE; TUBEROUS SCLEROSIS;

AUTISTIC DISORDER; BRAIN; HUMANS; NERVE NET; SYNAPSES;

EID: 84867426528     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2012.02.015     Document Type: Review

References (72)

1. Kanner L. Autistic disturbances of affective contact. Nervous Child 1943, 217-250.
2. Asperger H. Die autistischen Psychopathen im Kindesalter. Archiv für Psychiatrie und Nervenkrankheiten 1944, 76-136.
3. Heller T. Ueber Dementia infantilis. Zeitschrift fuer die Erforschung und Behandlung des Jugendlichen Schwachsinns 1908, 2:17-28.
4. Task Force on DSM-IV Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, American Psychiatric Association, Washington, DC. edn 4.
5. Geschwind D.H. Advances in autism. Annu Rev Med 2009, 60:367-380.
6. Cohen D., Pichard N., Tordjman S., Baumann C., Burglen L., Excoffier E., Lazar G., Mazet P., Pinquier C., Verloes A., et al. Specific genetic disorders and autism: clinical contribution towards their identification. J Autism Dev Disorders 2005, 35:103-116.
7. Betancur C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 2011, 1380:42-77.
8. Barabasi A.L., Gulbahce N., Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011, 12:56-68.
9. Goh K.I., Cusick M.E., Valle D., Childs B., Vidal M., Barabasi A.L. The human disease network. Proc Natl Acad Sci U S A 2007, 104:8685-8690.
10. Kim H.G., Kishikawa S., Higgins A.W., Seong I.S., Donovan D.J., Shen Y., Lally E., Weiss L.A., Najm J., Kutsche K., et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet 2008, 82:199-207.
11. Yan J., Noltner K., Feng J., Li W., Schroer R., Skinner C., Zeng W., Schwartz C.E., Sommer S.S. Neurexin 1alpha structural variants associated with autism. Neurosci Lett 2008, 438:368-370.
12. Wisniowiecka-Kowalnik B., Nesteruk M., Peters S.U., Xia Z., Cooper M.L., Savage S., Amato R.S., Bader P., Browning M.F., Haun C.L., et al. Intragenic rearrangements in NRXN1 in three families with autism spectrum disorder, developmental delay, and speech delay. Am J Med Genet B: Neuropsychiatr Genet 2010, 153B:983-993.
13. Feng J., Schroer R., Yan J., Song W., Yang C., Bockholt A., Cook E.H., Skinner C., Schwartz C.E., Sommer S.S. High frequency of neurexin 1beta signal peptide structural variants in patients with autism. Neurosci Lett 2006, 409:10-13.
14. Jamain S., Quach H., Betancur C., Rastam M., Colineaux C., Gillberg I.C., Soderstrom H., Giros B., Leboyer M., Gillberg C., et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003, 34:27-29.
15. Feyder M., Karlsson R.M., Mathur P., Lyman M., Bock R., Momenan R., Munasinghe J., Scattoni M.L., Ihne J., Camp M., et al. Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' syndrome. Am J Psychiatry 2010, 167:1508-1517.
16. Willatt L., Cox J., Barber J., Cabanas E.D., Collins A., Donnai D., FitzPatrick D.R., Maher E., Martin H., Parnau J., et al. 3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome. Am J Hum Genet 2005, 77:154-160.
17. Pinto D., Pagnamenta A.T., Klei L., Anney R., Merico D., Regan R., Conroy J., Magalhaes T.R., Correia C., Abrahams B.S., et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010, 466:368-372.
18. Durand C.M., Betancur C., Boeckers T.M., Bockmann J., Chaste P., Fauchereau F., Nygren G., Rastam M., Gillberg I.C., Anckarsater H., et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007, 39:25-27.
19. Berkel S., Marshall C.R., Weiss B., Howe J., Roeth R., Moog U., Endris V., Roberts W., Szatmari P., Pinto D., et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet 2010, 42:489-491.
20. Wilson H.L., Wong A.C., Shaw S.R., Tse W.Y., Stapleton G.A., Phelan M.C., Hu S., Marshall J., McDermid H.E. Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 2003, 40:575-584.
21. Bonaglia M.C., Giorda R., Mani E., Aceti G., Anderlid B.M., Baroncini A., Pramparo T., Zuffardi O. Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. J Med Genet 2006, 43:822-828.
22. Phelan K., McDermid H.E. The 22q13.3 deletion syndrome (Phelan-McDermid syndrome). Mol Syndromol 2011.
23. Jeffries A.R., Curran S., Elmslie F., Sharma A., Wenger S., Hummel M., Powell J. Molecular and phenotypic characterization of ring chromosome 22. Am J Med Genet A 2005, 137:139-147.
24. Misceo D., Rodningen O.K., Baroy T., Sorte H., Mellembakken J.R., Stromme P., Fannemel M., Frengen E. A translocation between Xq21.33 and 22q13.33 causes an intragenic SHANK3 deletion in a woman with Phelan-McDermid syndrome and hypergonadotropic hypogonadism. Am J Med Genet A 2011, 155A:403-408.
25. Moessner R., Marshall C.R., Sutcliffe J.S., Skaug J., Pinto D., Vincent J., Zwaigenbaum L., Fernandez B., Roberts W., Szatmari P., et al. Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 2007, 81:1289-1297.
26. Sheng M., Kim E. The Shank family of scaffold proteins. J Cell Sci 2000, 113(Pt 11):1851-1856.
27. Hayashi M.K., Tang C., Verpelli C., Narayanan R., Stearns M.H., Xu R.M., Li H., Sala C., Hayashi Y. The postsynaptic density proteins Homer and Shank form a polymeric network structure. Cell 2009, 137:159-171.
28. Baron M.K., Boeckers T.M., Vaida B., Faham S., Gingery M., Sawaya M.R., Salyer D., Gundelfinger E.D., Bowie J.U. An architectural framework that may lie at the core of the postsynaptic density. Science 2006, 311:531-535.
29. Tu J.C., Xiao B., Naisbitt S., Yuan J.P., Petralia R.S., Brakeman P., Doan A., Aakalu V.K., Lanahan A.A., Sheng M., et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 1999, 23:583-592.
30. Sala C., Piech V., Wilson N.R., Passafaro M., Liu G., Sheng M. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron 2001, 31:115-130.
31. Roussignol G., Ango F., Romorini S., Tu J.C., Sala C., Worley P.F., Bockaert J., Fagni L. Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. J Neurosci 2005, 25:3560-3570.
32. Hung A.Y., Futai K., Sala C., Valtschanoff J.G., Ryu J., Woodworth M.A., Kidd F.L., Sung C.C., Miyakawa T., Bear M.F., et al. Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. J Neurosci 2008, 28:1697-1708.
33. Peca J., Feliciano C., Ting J.T., Wang W., Wells M.F., Venkatraman T.N., Lascola C.D., Fu Z., Feng G. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 2011, 472:437-442.
34. Bangash M.A., Park J.M., Melnikova T., Wang D., Jeon S.K., Lee D., Syeda S., Kim J., Kouser M., Schwartz J., et al. Enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism. Cell 2011, 145:758-772.
35. Wang X., McCoy P.A., Rodriguiz R.M., Pan Y., Je H.S., Roberts A.C., Kim C.J., Berrios J., Colvin J.S., Bousquet-Moore D., et al. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet 2011, 20:3093-3108.
36. Bozdagi O., Sakurai T., Papapetrou D., Wang X., Dickstein D.L., Takahashi N., Kajiwara Y., Yang M., Katz A.M., Scattoni M.L., et al. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism 2010, 1:15.
37. Bockers T.M., Segger-Junius M., Iglauer P., Bockmann J., Gundelfinger E.D., Kreutz M.R., Richter D., Kindler S., Kreienkamp H.J. Differential expression and dendritic transcript localization of Shank family members: identification of a dendritic targeting element in the 3' untranslated region of Shank1 mRNA. Mol Cell Neurosci 2004, 26:182-190.
38. Consortium E.C.T.S. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993, 75:1305-1315.
39. van Slegtenhorst M., de Hoogt R., Hermans C., Nellist M., Janssen B., Verhoef S., Lindhout D., van den Ouweland A., Halley D., Young J., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277:805-808.
40. Crino P.B., Nathanson K.L., Henske E.P. The Tuberous Sclerosis Complex. N Engl J Med 2006, 355:1345-1356.
41. Smalley S.L. Autism and tuberous sclerosis. J Autism Dev Disorders 1998, 28:407-414.
42. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4:648-657.
43. Tang S.J., Reis G., Kang H., Gingras A.C., Sonenberg N., Schuman E.M. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A 2002, 99:467-472.
44. Ehninger D., Han S., Shilyansky C., Zhou Y., Li W., Kwiatkowski D.J., Ramesh V., Silva A.J. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 2008, 14:843-848.
45. Tavazoie S.F., Alvarez V.A., Ridenour D.A., Kwiatkowski D.J., Sabatini B.L. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci 2005, 8:1727-1734.
46. Sakai Y., Shaw C.A., Dawson B.C., Dugas D.V., Al-Mohtaseb Z., Hill D.E., Zoghbi H.Y. Protein interactome reveals converging molecular pathways among autism disorders. Sci Transl Med 2011, 3:86ra49.
47. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y., Mele A., Fraser C.E., Stone E.F., Chen C., Fak J.J., Chi S.W., et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261.
48. Auerbach B.D., Osterweil E.K., Bear M.F. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 2011, 480:63-68.
49. Verkerk A.J., Pieretti M., Sutcliffe J.S., Fu Y.H., Kuhl D.P., Pizzuti A., Reiner O., Richards S., Victoria M.F., Zhang F.P., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991, 65:905-914.
50. De Boulle K., Verkerk A.J., Reyniers E., Vits L., Hendrickx J., Van Roy B., Van den Bos F., de Graaff E., Oostra B.A., Willems P.J. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat Genet 1993, 3:31-35.
51. Hatton D.D., Sideris J., Skinner M., Mankowski J., Bailey D.B., Roberts J., Mirrett P. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A 2006, 140A:1804-1813.
52. Feng Y., Gutekunst C.A., Eberhart D.E., Yi H., Warren S.T., Hersch S.M. Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci: Official J Soc Neurosci 1997, 17:1539-1547.
53. Brown V., Jin P., Ceman S., Darnell J.C., O'Donnell W.T., Tenenbaum S.A., Jin X., Feng Y., Wilkinson K.D., Keene J.D., et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001, 107:477-487.
54. Kindler S., Kreienkamp H.J. The role of the postsynaptic density in the pathology of the fragile X syndrome. Results Problems Cell Differ 2012, 54:61-80.
55. Huber K.M., Kayser M.S., Bear M.F. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science 2000, 288:1254-1257.
56. Huber K.M., Gallagher S.M., Warren S.T., Bear M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 2002, 99:7746-7750.
57. Dolen G., Osterweil E., Rao B.S., Smith G.B., Auerbach B.D., Chattarji S., Bear M.F. Correction of fragile X syndrome in mice. Neuron 2007, 56:955-962.
58. Krueger D.D., Bear M.F. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 2011, 62:411-429.
59. Schutt J., Falley K., Richter D., Kreienkamp H.J., Kindler S. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J Biol Chem 2009, 284:25479-25487.
60. Kishino T., Lalande M., Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 1997, 15:70-73.
61. Matsuura T., Sutcliffe J.S., Fang P., Galjaard R.J., Jiang Y.H., Benton C.S., Rommens J.M., Beaudet A.L. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 1997, 15:74-77.
62. Glessner J.T., Wang K., Cai G., Korvatska O., Kim C.E., Wood S., Zhang H., Estes A., Brune C.W., Bradfield J.P., et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009, 459:569-573.
63. Dindot S.V., Antalffy B.A., Bhattacharjee M.B., Beaudet A.L. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet 2008, 17:111-118.
64. Yashiro K., Riday T.T., Condon K.H., Roberts A.C., Bernardo D.R., Prakash R., Weinberg R.J., Ehlers M.D., Philpot B.D. Ube3a is required for experience-dependent maturation of the neocortex. Nat Neurosci 2009, 12:777-783.
65. Mabb A.M., Judson M.C., Zylka M.J., Philpot B.D. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. Trends Neurosci 2011, 34:293-303.
66. Smith S.E., Zhou Y.D., Zhang G., Jin Z., Stoppel D.C., Anderson M.P. Increased gene dosage of Ube3a results in autism traits and decreased glutamate synaptic transmission in mice. Sci Transl Med 2011, 3:103ra197.
67. Ehlers M.D. Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci 2003, 6:231-242.
68. Giacometti E., Luikenhuis S., Beard C., Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci U S A 2007, 104:1931-1936.
69. Guy J., Gan J., Selfridge J., Cobb S., Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007, 315:1143-1147.
70. Welch J.M., Lu J., Rodriguiz R.M., Trotta N.C., Peca J., Ding J.D., Feliciano C., Chen M., Adams J.P., Luo J., et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 2007, 448:894-900.
71. Zeier Z., Kumar A., Bodhinathan K., Feller J.A., Foster T.C., Bloom D.C. Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. Gene Ther 2009, 16:1122-1129.
72. Zuchner S., Wendland J.R., Ashley-Koch A.E., Collins A.L., Tran-Viet K.N., Quinn K., Timpano K.C., Cuccaro M.L., Pericak-Vance M.A., Steffens D.C., et al. Multiple rare SAPAP3 missense variants in trichotillomania and OCD. Mol Psychiatry 2009, 14:6-9.